Adults who have immunocompromising conditions should receive the 13-valent pneumococcal conjugate vaccine (Prevnar 13, PCV13) in addition to the 23-serotype polysaccharide vaccine (Pneumovax 23, PPSV23), according to the CDC's Advisory Committee on Immunization Practices. Read the full article here.